Inhaled insulin (Exubera®): combining efficacy and convenience
نویسندگان
چکیده
منابع مشابه
Inhaled human insulin (Exubera®): clinical profile and patient considerations
Inhaled human insulin (Exubera) is a rapid-acting regular human insulin administered by oral inhalation before meals. It provides a non-invasive alternative to multiple subcutaneous injections for the treatment of hyperglycemia in adult patients with type 1 and type 2 diabetes. Compared with subcutaneous rapid-acting insulin analogs, Exubera provides equivalent HbA1c control. As a monotherapy o...
متن کاملTwo-Year Pulmonary Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 2 Diabetes
OBJECTIVE The purpose of this study was to evaluate the 2-year pulmonary safety of inhaled human insulin (Exubera [EXU]) in 635 nonsmoking adults with type 2 diabetes. RESEARCH DESIGN AND METHODS Patients were randomly assigned to receive prandial EXU or subcutaneous insulin (regular or short-acting) plus basal (intermediate- or long-acting) insulin. The primary end points were the annual rat...
متن کاملInhaled human insulin (Exubera(®)): its pharmacologic profile, efficacy and safety in the treatment of adults with diabetes mellitus.
Exubera(®) (EXU, insulin human [rDNA origin]) is the first inhaled insulin approved for the treatment of diabetes in adults. Its pharmacokinetic properties make it suitable as therapy for postprandial glycemia. Clinical trials have demonstrated equal efficacy with short-acting subcutaneous regular and analog insulin in both Type 1 and 2 diabetes, and have also shown that it has value as adjunct...
متن کاملTwo-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes.
OBJECTIVE The purpose of this study was to evaluate the long-term (2-year) safety and efficacy of inhaled human insulin (Exubera [insulin human (rDNA origin)] inhalation powder) (EXU) in adult patients with type 1 diabetes. RESEARCH DESIGN AND METHODS Patients were randomly assigned to receive EXU (n = 290) or subcutaneous (s.c.) insulin (n = 290), plus basal (intermediate- or long-acting) in...
متن کاملAn assessment of eligibility for inhaled insulin (Exubera): the Fremantle Diabetes Study.
The product information (1) for human insulin inhalation powder (Exubera; Pfizer) recommends spirometry at baseline, 6 months postinitiation, and at least annually thereafter. Patients with a forced expiratory volume in the first second (FEV1) 70% of that predicted for age, sex, and height should not start Exubera. In those exhibiting 20% decline in FEV1 during follow-up, Exubera should be disc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes and Vascular Disease Research
سال: 2006
ISSN: 1479-1641,1752-8984
DOI: 10.3132/dvdr.2006.027